Andy Surinach

705 total citations
74 papers, 430 citations indexed

About

Andy Surinach is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Andy Surinach has authored 74 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 19 papers in Epidemiology. Recurrent topics in Andy Surinach's work include Pancreatic and Hepatic Oncology Research (26 papers), Cancer Genomics and Diagnostics (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Andy Surinach is often cited by papers focused on Pancreatic and Hepatic Oncology Research (26 papers), Cancer Genomics and Diagnostics (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Andy Surinach collaborates with scholars based in United States, Switzerland and United Kingdom. Andy Surinach's co-authors include Paul Cockrum, Frank A. Corvino, Steven R. Arikian, Deepa Malhotra, G. Binder, Shu Wang, Shivani K. Mhatre, Sumanta K. Pal, Yasir M. Nagarwala and Leah J. McGrath and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Andy Surinach

66 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andy Surinach United States	13	199	81	78	72	70	74	430
Robert Hettle United Kingdom	11	265 1.3×	95 1.2×	64 0.8×	72 1.0×	27 0.4×	63	547
Aparna Hegde United States	11	476 2.4×	147 1.8×	75 1.0×	57 0.8×	40 0.6×	31	642
Gary Crouch United States	8	98 0.5×	115 1.4×	25 0.3×	122 1.7×	89 1.3×	14	408
Ardine Reedijk Netherlands	14	144 0.7×	37 0.5×	41 0.5×	64 0.9×	98 1.4×	23	500
Andrew J. Klink United States	13	149 0.7×	151 1.9×	46 0.6×	102 1.4×	136 1.9×	61	524
Abraham Klepfish Israel	12	151 0.8×	41 0.5×	40 0.5×	63 0.9×	129 1.8×	21	486
Michelle Rashford United States	7	226 1.1×	60 0.7×	70 0.9×	59 0.8×	27 0.4×	10	640
Fadi Nasr Lebanon	11	184 0.9×	86 1.1×	29 0.4×	32 0.4×	57 0.8×	65	357
Philip A. Stevenson United States	14	199 1.0×	71 0.9×	52 0.7×	63 0.9×	298 4.3×	45	733
Andrew Shields United States	11	285 1.4×	171 2.1×	70 0.9×	98 1.4×	29 0.4×	30	608

Countries citing papers authored by Andy Surinach

Since Specialization

Citations

This map shows the geographic impact of Andy Surinach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andy Surinach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andy Surinach more than expected).

Fields of papers citing papers by Andy Surinach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andy Surinach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andy Surinach. The network helps show where Andy Surinach may publish in the future.

Co-authorship network of co-authors of Andy Surinach

This figure shows the co-authorship network connecting the top 25 collaborators of Andy Surinach. A scholar is included among the top collaborators of Andy Surinach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andy Surinach. Andy Surinach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Crown, William H., Rafael Alfonso‐Cristancho, Andy Surinach, et al.. (2025). Research Method, Conduct, and Reporting Considerations for Improving the Quality of Non-Hypothesis-Evaluating Treatment Effectiveness Analyses Using Real-World Data: An ISPOR Working Group Report. Value in Health. 28(7). 979–987.

Flora, Darcy R., Andrew M. Evens, Michelle A. Fanale, et al.. (2023). The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional survey. Supportive Care in Cancer. 31(11). 664–664.

Winter, Allison, et al.. (2023). Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States. Clinical Lymphoma Myeloma & Leukemia. 23(7). 527–534. 5 indexed citations

Exuzides, Alex, Tu My To, Ibrahim M. Abbass, et al.. (2022). Healthcare resource utilization and costs in individuals with Huntington’s disease by disease stage in a US population. Journal of Medical Economics. 25(1). 722–729. 5 indexed citations

Moore, Kathleen N., et al.. (2022). Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer. Gynecologic Oncology. 169. 113–117. 5 indexed citations

Musa, Fernanda, Elizabeth Brouwer, Naomi Schwartz, et al.. (2022). Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer. Gynecologic Oncology. 164(3). 645–650. 12 indexed citations

Palanca-Wessels, Maria Corinna, et al.. (2021). PCN157 Characteristics and Treatment Patterns Among Patients Diagnosed with Metastatic Colorectal Cancer in the United States: A Healthcare Claims Database Analysis. Value in Health. 24. S48–S49. 1 indexed citations

Exuzides, Alex, Daniel Sheinson, Páris Sidiropoulos, et al.. (2021). Burden and cost of comorbidities in patients with neuromyelitis optica spectrum disorder. Journal of the Neurological Sciences. 427. 117530–117530. 16 indexed citations

Surinach, Andy, et al.. (2021). 1513P Real-world treatment discontinuation patterns among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States. Annals of Oncology. 32. S1107–S1108.

10.

Morgans, Alicia K., Matt D. Galsky, Zsolt Hepp, et al.. (2021). 704P Treatment patterns among patients with advanced urothelial carcinoma (aUC) in the USA. Annals of Oncology. 32. S714–S715. 6 indexed citations

11.

George, Ben, et al.. (2021). The Association of Real-World CA 19-9 Level Monitoring Patterns and Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Frontiers in Oncology. 11. 754687–754687. 15 indexed citations

12.

Sadetsky, Natalia, et al.. (2020). Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER‐Medicare analysis. Cancer Medicine. 9(17). 6216–6224. 5 indexed citations

13.

Cockrum, Paul, et al.. (2020). 1564P Clinical pathway implications and real-world characteristics and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with first line category 1 National Comprehensive Cancer Network (NCCN) regimens. Annals of Oncology. 31. S953–S954. 1 indexed citations

14.

Mileshkin, Linda, Tilmann Bochtler, Andreas Beringer, et al.. (2020). 519P Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study. Annals of Oncology. 31. S459–S459. 2 indexed citations

15.

Shewade, Ashwini, Adam J. Olszewski, Andy Surinach, et al.. (2020). Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States. Blood. 136(Supplement 1). 6–8. 6 indexed citations

16.

Surinach, Andy, et al.. (2020). Prolonged Response to Liposomal Irinotecan in a Patient with Stage IV Pancreatic/Bile Duct Cancer Previously Treated with FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel. Current Oncology. 27(2). 222–225. 1 indexed citations

17.

Drakaki, Alexandra, Allan J. Pantuck, Shivani K. Mhatre, et al.. (2020). “Real-world” outcomes and prognostic indicators among patients with high-risk muscle-invasive urothelial carcinoma. Urologic Oncology Seminars and Original Investigations. 39(1). 76.e15–76.e22. 10 indexed citations

18.

Radford, John, Felipe A. Castro, Anshuman Chaturvedi, et al.. (2019). Treatment Patterns and Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Experience from a Single UK Centre. Blood. 134(Supplement_1). 2917–2917. 5 indexed citations

19.

Surinach, Andy, et al.. (2019). PCN16 IMPACT OF TREATMENT SEQUENCE ON OVERALL SURVIVAL IN METASTATIC PANCREATIC CANCER PATIENTS TREATED WITH LIPOSOMAL IRINOTECAN IN THE REAL-WORLD SETTING. Value in Health. 22. S58–S58. 1 indexed citations

20.

Pal, Sumanta K., Jun Gong, Shivani K. Mhatre, et al.. (2019). Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer. 19(1). 548–548. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact